CN120478602A - 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物 - Google Patents

使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物

Info

Publication number
CN120478602A
CN120478602A CN202510640885.XA CN202510640885A CN120478602A CN 120478602 A CN120478602 A CN 120478602A CN 202510640885 A CN202510640885 A CN 202510640885A CN 120478602 A CN120478602 A CN 120478602A
Authority
CN
China
Prior art keywords
dolapride
dose
week
once
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510640885.XA
Other languages
English (en)
Chinese (zh)
Inventor
D·A·科克斯
Z·米利塞维奇
谭丽珊
A·G·维尔纳
D·B·伍德沃德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN120478602(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN120478602A publication Critical patent/CN120478602A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202510640885.XA 2017-11-21 2018-11-13 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物 Pending CN120478602A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21
US62/589244 2017-11-21
PCT/US2018/060716 WO2019103875A2 (en) 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide
CN201880075369.5A CN111356472A (zh) 2017-11-21 2018-11-13 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880075369.5A Division CN111356472A (zh) 2017-11-21 2018-11-13 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物

Publications (1)

Publication Number Publication Date
CN120478602A true CN120478602A (zh) 2025-08-15

Family

ID=64572530

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510640885.XA Pending CN120478602A (zh) 2017-11-21 2018-11-13 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物
CN201880075369.5A Pending CN111356472A (zh) 2017-11-21 2018-11-13 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880075369.5A Pending CN111356472A (zh) 2017-11-21 2018-11-13 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物

Country Status (22)

Country Link
US (2) US11576950B2 (enExample)
EP (1) EP3713593A2 (enExample)
JP (3) JP7221956B2 (enExample)
KR (2) KR20220146656A (enExample)
CN (2) CN120478602A (enExample)
AU (2) AU2018372709B2 (enExample)
BR (1) BR112020007817A2 (enExample)
CA (1) CA3082625A1 (enExample)
CL (1) CL2020001252A1 (enExample)
CR (1) CR20200202A (enExample)
DO (1) DOP2020000104A (enExample)
EA (1) EA202090971A1 (enExample)
EC (1) ECSP20026436A (enExample)
IL (1) IL274563B2 (enExample)
JO (1) JOP20200126A1 (enExample)
MA (1) MA50798A (enExample)
MX (1) MX2020005231A (enExample)
PE (1) PE20200847A1 (enExample)
PH (1) PH12020550795A1 (enExample)
SG (1) SG11202003687RA (enExample)
UA (1) UA127588C2 (enExample)
WO (1) WO2019103875A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7728176B2 (ja) * 2019-03-15 2025-08-22 イーライ リリー アンド カンパニー 保存製剤
MX2022009383A (es) * 2020-01-30 2022-11-07 Lilly Co Eli Usos terapéuticos de dulaglutida.
EP4153130A1 (en) * 2020-05-19 2023-03-29 F. Hoffmann-La Roche AG The use of chelators for the prevention of visible particle formation in parenteral protein solutions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
EA011166B1 (ru) 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
EA201070121A1 (ru) 2007-07-10 2010-06-30 Эли Лилли Энд Компани Лекарственная форма, содержащая слитый белок glp-1-fc
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
JP7191043B2 (ja) 2017-06-01 2022-12-16 イーライ リリー アンド カンパニー 慢性腎疾患の治療のためのデュラグルチド

Also Published As

Publication number Publication date
UA127588C2 (uk) 2023-10-25
IL274563B2 (en) 2023-12-01
AU2022203372B2 (en) 2025-04-10
AU2018372709B2 (en) 2022-04-28
US11576950B2 (en) 2023-02-14
US20200330558A1 (en) 2020-10-22
KR20200076705A (ko) 2020-06-29
SG11202003687RA (en) 2020-06-29
CR20200202A (es) 2020-08-20
AU2022203372A1 (en) 2022-06-09
ECSP20026436A (es) 2020-06-30
BR112020007817A2 (pt) 2020-10-06
EP3713593A2 (en) 2020-09-30
CN111356472A (zh) 2020-06-30
PH12020550795A1 (en) 2021-04-19
IL274563A (en) 2020-06-30
JOP20200126A1 (ar) 2020-05-21
WO2019103875A3 (en) 2019-07-25
NZ763815A (en) 2023-11-24
JP7221956B2 (ja) 2023-02-14
JP2024056908A (ja) 2024-04-23
WO2019103875A2 (en) 2019-05-31
KR102589234B1 (ko) 2023-10-16
CA3082625A1 (en) 2019-05-31
AU2018372709A1 (en) 2020-05-14
EA202090971A1 (ru) 2020-08-07
IL274563B1 (en) 2023-08-01
JP2021502379A (ja) 2021-01-28
US20240189394A1 (en) 2024-06-13
KR20220146656A (ko) 2022-11-01
MX2020005231A (es) 2020-08-24
CL2020001252A1 (es) 2020-10-30
JP2022062153A (ja) 2022-04-19
MA50798A (fr) 2020-09-30
DOP2020000104A (es) 2020-08-31
PE20200847A1 (es) 2020-08-18

Similar Documents

Publication Publication Date Title
JP2024129139A (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
JP7475398B2 (ja) 医学療法におけるセマグルチド
JP2024056908A (ja) デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
CN110267648A (zh) 毒蜥外泌肽(9-39)的缓冲制剂
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
KR20250111397A (ko) 제2형 당뇨병 (t2d), 비만, 또는 적어도 하나의 체중 관련된 동반질환이 있는 과체중을 갖는 대상체를 치료하기 위한 오르포르글리프론의 투약 요법
TWI745114B (zh) 用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品
EP4043033A1 (en) Pharmaceutical composition which can be used for prevention and/or treatment of acquired hemophilia a, and product comprising said pharmaceutical composition
KR20220063157A (ko) 빌다글립틴 및 메트포르민을 이용한 조합 요법
EA041605B1 (ru) Способы применения и композиции, содержащие дулаглутид
WO2021052472A1 (zh) 抗pcsk9抗体用于预防或治疗胆固醇相关疾病的方法
Sarfraz et al. Mechanisms and Biologic Treatment Strategies in Immune-Mediated Ocular Inflammation
McKeirnan et al. Immunizations and Diabetes
CN120641091A (zh) (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗糖尿病和前驱糖尿病中的用途
CN120227455A (zh) 包含与乙型肝炎病毒表面抗原（HBsAg）特异性结合的抗体组合物
JP2025529212A (ja) 療法に使用するためのｇｉｐ／ｇｌｐ１
Samuel et al. A Retrospective Comparison Study between the Effectiveness and Safety of Fixed Dose Combination of Vildagliptin versus Sitagliptin with Metformin in Type 2 Diabetes Mellitus Patients
Sears et al. 2008 new drug approvals

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination